Literature DB >> 10895069

Bcl-2 expression in cholangiocellular carcinoma is inversely correlated with biologically aggressive phenotypes.

Y Ito1, T Takeda, Y Sasaki, M Sakon, M Monden, T Yamada, S Ishiguro, S Imaoka, M Tsujimoto, N Matsuura.   

Abstract

bcl-2 is known to play a crucial role in modulating carcinoma progression as well as in inhibiting apoptosis. However, its expression and clinical significance for cholangiocellular carcinoma (CCC) remains unclear. In the present study, we immunohistochemically investigated bcl-2 expression in 41 CCC. Thirteen cases (31.7%) were classified as bcl-2 positive, because more than 10% of the carcinoma cells expressed bcl-2. The expression of bcl-2 was inversely related to lymph node metastasis, vascular invasion, perineural invasion, the Ki-67 labeling index, aberrant p53 expression and the incidence of apoptotic cells. Furthermore, well or moderately differentiated carcinoma more frequently expressed bcl-2. These results suggest that downregulation of bcl-2 expression is strongly linked to highly biologically aggressive phenotypes of CCC. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10895069     DOI: 10.1159/000012139

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  11 in total

1.  Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.

Authors:  Holger G Hass; Oliver Nehls; Juergen Jobst; Andrea Frilling; Ulrich Vogel; Stephan Kaiser
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

2.  Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis.

Authors:  L Yang; S Feng; Y Yang
Journal:  Cancer Gene Ther       Date:  2016-11-18       Impact factor: 5.987

3.  Detection of bcl-2 and bax expression and bcl-2/JH fusion gene in intrahepatic cholangiocarcinoma.

Authors:  Lin-Lang Guo; Sha Xiao; Ying Guo
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

4.  Regional differences in gallbladder cancer pathogenesis: insights from a comparison of cell cycle-regulatory, PI3K, and pro-angiogenic protein expression.

Authors:  Jean M Butte; Javiera Torres; Emanuela F Veras; Kenichi Matsuo; Mithat Gönen; Michael I D'Angelica; Enrique Waugh; Manuel Meneses; Yoshiyaki Inayama; Yuman Fong; Ronald P Dematteo; Hernan De La Fuente; Itaru Endo; David S Klimstra; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2012-12-01       Impact factor: 5.344

5.  New advances in the management of biliary tract cancer.

Authors:  John Bridgewater; Charles Imber
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

6.  Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma.

Authors:  Myung Ah Lee; In Sook Woo; Jin-Hyoung Kang; Young Seon Hong; Kyung Shik Lee
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-28       Impact factor: 4.553

7.  Expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia.

Authors:  Sheng-Mian Li; Shu-Kun Yao; Nobuyoshi Yamamura; Toshitsugu Nakamura
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

8.  Diosgenin Suppresses Cholangiocarcinoma Cells Via Inducing Cell Cycle Arrest And Mitochondria-Mediated Apoptosis.

Authors:  Xiao-Mei Mao; Pan Zhou; Si-Yang Li; Xiao-Yun Zhang; Jin-Xing Shen; Qing-Xi Chen; Jiang-Xing Zhuang; Dong-Yan Shen
Journal:  Onco Targets Ther       Date:  2019-11-04       Impact factor: 4.147

9.  Altered expression of cellular Bcl-2 in the progression of hamster cholangiocarcinogenesis.

Authors:  Byung-Suk Jeon; Byung-Il Yoon
Journal:  ScientificWorldJournal       Date:  2012-04-30

10.  A study of mifepristone/IFN-γ-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro.

Authors:  Qi-Long Sun; Xu-Guang Zhang; Quan-Tai Xing; Peng Ding; Jin-Bo Feng; Xiao-Peng Wu; Zhan-Min Wang
Journal:  Onco Targets Ther       Date:  2012-11-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.